Axsome Therapeutics, Inc. (AXSM)
Why Is Axsome (AXSM) Up 19.2% Since Last Earnings Report?
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y
Axsome posts narrower second-quarter loss and 72% revenue surge, driven by strong Auvelity sales.
Axsome Therapeutics, Inc. (AXSM) Q2 2025 Earnings Call Transcript
Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q2 2025 Earnings Conference Call August 4, 2025 8:00 AM ET Company Participants Ari Maizel - Chief Commercial Officer Darren Opland - Corporate Participant Herriot Tabuteau - Founder, Chairman, CEO & President Nick Pizzie - Chief Financial Officer Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Asim Rana - Truist Securities, Inc., Research Division David A. Amsellem - Piper Sandler & Co., Research Division David Timothy Hoang - Deutsche Bank AG, Research Division Graig C.
Here's What Key Metrics Tell Us About Axsome (AXSM) Q2 Earnings
While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Axsome Therapeutics (AXSM) Reports Q2 Loss, Beats Revenue Estimates
Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to a loss of $1.24 per share a year ago.
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Axsome (AXSM) Down 1.8% Since Last Earnings Report?
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y
Axsome reports better-than-expected first quarter 2025 results. Net product revenues surge year over year on strong Auvelity sales.
Axsome Therapeutics, Inc. (AXSM) Q1 2025 Earnings Call Transcript
Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q1 2025 Earnings Conference Call May 5, 2025 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - CEO Nick Pizzie - CFO Ari Maizel - Chief Commercial Officer Mark Jacobson - COO Hunter Murdock - General Counsel Conference Call Participants Leonid Timashev - RBC Capital Markets Marc Goodman - Leerink Partners Andrew Tsai - Jefferies Ash Verma - UBS Ram Selvaraju - H.C. Wainwright Charles Duncan - Cantor Fitzgerald David Amsellem - Piper Sandler David Hoang - Deutsche Bank Joon Lee - Truist Securities Cerena Chen - Wells Fargo Jason Gerberry - Bank of America Graig Suvannavejh - Mizuho Securities Yatin Suneja - Guggenheim Partners Myles Minter - William Blair Troy Langford - TD Cowen Ami Fadia - Needham & Company Operator Greetings, and welcome to the Axsome Therapeutics First Quarter 2025 Conference Call and Webcast.
Axsome (AXSM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Axsome Therapeutics (AXSM) Reports Q1 Loss, Tops Revenue Estimates
Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to loss of $1.09 per share a year ago.
Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
